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ABSTRACT 
Objective: Was to create the composition of the liposomal pharmaceutical form for injections of somatostatin analogue cyphetrylin using soybean 
phosphatidylcholine (SPC).  
Methods: The cyphetrylin, active pharmaceutical ingredient (API), developed in the Chemical Synthesis Laboratory, the N. N. Blokhin National Medical 
Research Center of Oncology of the Ministry of Health of the Russian Federation; SPC and polyethylene glycol-2000-
distearoylphosphatidylethanolamine (PEG-DSPE, Lipoid, Germany); cholesterol ≥99% (Sigma-Aldrich, Japan). The lipid film hydration method with 
subsequent liposomal dispersion filtration/extrusion through nylon membrane filters was used for the phospholipid vesicle production. Based on API 
and lipid components in different molar ratios, we studied over 15 model liposomal compositions and assessed each lipid's impact in use on quality 
attributes of resulting dispersions. Derived model samples of liposomal dispersion were estimated in terms of quality and efficiency of cyphetrylin 
encapsulation into vesicles, their average size and the surface charge (zeta potential), polydispersity index (PDI) and dispersion viscosity. We used 
spectral photometry, dispersion laser spectroscopy, electrophoretic particle mobility assay, and viscometry to assess these features.  
Results: Pharmaceutical form components' desirable molar ratios determined: cyphetrylin/SPC at 1:60.0 and SPC/cholesterol/PEG-DSPE at 
1:0.2:0.004, were determined. This composition allows cyphetrylin liposomal dispersion production with relatively stable vesicles of uniform size, 
176 nm in diameter, and a 100% maximum rate of API encapsulation into the bilayer. 
Conclusion: Technological and chemical/pharmaceutical studies resulted in selecting a preferable composition of an injectable liposomal 
pharmaceutical form model of somatostatin analog-based on the SPC. 
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INTRODUCTION 
The concept of the liposomal system of active pharmaceutical 
ingredients (API) delivery revolutionized the pharmaceutical market. 
Liposomes, initially called “bangosomes”, were discovered and first 
described in 1965 by the British biophysicist Alec Bangham and his 
colleagues at Babraham Institute in Cambridge. Since then, liposomes 
have evolved from a simple cellular membrane model into an actively 
studied and applied to a delivery system for API of a different origin. 
So far, the FDA has authorized the clinical use of 15 liposomal 
substances in various medicine fields: oncology, dermatology, 
anesthesiology, and treatment of infectious diseases. All these 
medicinal products resemble free API for their main clinical effect. 
However, their toxicological criteria compare favourably, which 
improves the tolerance of these medicinal products, the costs of 
eliminating the adverse toxic events, and, consequently, the patient's 
quality of life. Besides, ca. 30 liposome-based developments, mostly 
intended to treat cancers, are now in the clinical trials pipeline [1−3].  
There are no alternative delivery systems with all properties 
inherent in liposomes now. These nanostructures are biocompatible 
and biodegradable, which allows for their parenteral administration. 
Liposomes protect the surrounding body tissues from API cytotoxic 
action, fortifying the active substance against enzymatic destruction 
and extending the effect of API introduced into the body, and are 
capable of targeting delivery of API to organs, tissues, and individual 
cells. The liposomal delivery system allows for the encapsulation of 
both water-retaining and water-repellent substances, facilitating the 
production of their water-soluble forms and thus improving their 
bioavailability. It is essential because the amount of water-insoluble 
and not readily water-soluble in API has increased recently [4−6]. 
We counted approximately 75% new candidate substances for 
therapeutic product development, which are not readily water-
soluble; most are antitumor agents. Poor water solubility is the 
integral property of many antitumor drugs for two main reasons. 
Firstly, candidate drugs' physical and chemical properties rarely 
focus on the screening of substances for antitumor activity. 
Secondly, to achieve permeability, activity, and stability, an 
antitumor agent must contain certain hydrophobic structural 
features that make API not freely water-soluble [7]. 
The Chemical Synthesis Laboratory of N. N. Blokhin National Medical 
Research Center of Oncology of the Ministry of Health of the Russian 
Federation derived a hydrophobic somatostatin analogue, 
cyphetrylin, with antitumor activity. Unlike other somatostatin 
equivalents, cyphetrylin is a non-cyclical peptide derived with 
classical peptide chemistry methods. By its chemical structure, 
cyphetrylin is a methyl ether of Nα-tret-butyloxycarbonyl-S-
tetrahydropyranyl, cysteine phenyl, alanyl-D-tryptophyl-Nε-
carbobenzoxylysyl threonine (fig. 1). All lateral reactive groups in its 
molecule are protected with tert-butyloxycarbonyl, 
benzyloxycarbonyl, and tetrahydropynal groups. In vivo studies, 
cyphetrylin inhibits the secretion of growth hormone, prolactin and 
insulin secretion. Cyphetrylin antitumor activity shown in 
continuous cell lines of mouse tumors: adenocarcinoma of the breast 
Ca755, human breast cancer BrC1, cervical cancer CC5, Lewis lung 
carcinoma LLC, and those of rat tumors: prostatic adenocarcinoma 
R-3327-H and DMBA-induced breast tumors [8−10].  
 
 
Fig. 1: Cyphetrylin structural formula. Legend: R–tret-
butyloxycarbonyl, R1–tetrahydropyranyl, R2–
carbobenzyloxycarbonyl, R3–methyl 
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With the view to hydrophobic properties of cyphetrylin, the 
Pharmaceutical Form Development Laboratory of N. N. Blokhin 
National Medical Research Center of Oncology of the Ministry of 
Health of Russian Federation derived cyphetrylin a solid 
pharmaceutical dosage form of tablets, which has already passed 
Stage I clinical trials in patients with neuroendocrine tumors 
[11−14]. It was proposed to develop the liposome-based injectable 
pharmaceutical form as an alternative to cyphetrylin tablets, to 
improve its efficacy and mitigate adverse events.  
MATERIALS AND METHODS 
Мaterials 
Cyphetrylin substance (N. N. Blokhin National Medical Research 
Center of Oncology of the Ministry of Health of Russian Federation), 
soybean phosphatidylcholine (SPC, Lipoid, Germany), cholesterol 
≥99% (Sigma-Aldrich, Japan), polyethylene glycol-2000-
distearoylphosphatidylethanolamine (PEG-DSPE, Lipoid, Germany), 
chloroform stabilized with ethanol (Сhimmed, Russia), 95% ethanol 
(Flora Kavkaza OSJC, Russia), water for injections; 1.2 um, 0.45 um 
and 0.22 um Pall nylon membrane filters, N66, d 25 mm (Pall 
Eurasia LLC, Russia).  
Мethods 
Production of liposomes with cyphetrylin 
To produce cyphetrylin liposomes, we used the Bangham method [15]. 
Cyphetrylin substance and lipid components (SPC, cholesterol, and PEG-
DSPE) were dissolved in chloroform. We transferred the resulting 
solution into a round-bottom flask and removed the organic solvents by 
vacuuming a Heidolph Hei-VAP Advantage rotary evaporator (Heidolph, 
Germany) at low-pressure at+(40±1) °С water bath until the film became 
evenly distributed on the formed flask walls. The lipid film was 
terminally dried in a vacuum (120−125 mbar) until the organic solvent 
residues were removed and then hydrated with water for injection to 
produce large multi-layer liposomes dispersion with the theoretical 
active substance concentration of 1.0 mg/ml. To reduce cyphetrylin 
liposomes size, the dispersion was successively screened through 1.2 
um, 0.45 um, and 0.22 um nylon membranes in the LipexTM extruder 
(Northern Lipids, Canada). “Empty” liposomes were generated in the 
same way as those with an active substance, but without adding 
cyphetrylin to the drug components organic solution. Using cyphetrylin, 
SPC, cholesterol, and PEG-DSPE, we generated and tested 15 model 
compositions of cyphetrylin in the liposomal pharmaceutical dosage 
form with different components molar ratios (table 1) [16]. 
  
Table 1: Model compositions of the liposomal dosage form of cyphetrylin 
Formula Molar ratio 
Cyphetrylin/SPC SPC/cholesterol/PEG-DSPE 
F1 1:70.0 1:0.2:0.004 
F2 1:70.0 1:0.1:0.004 
F3 1:67.5 1:0.2:0.004 
F4 1:67.5 1:0.1:0.004 
F5 1:65.0 1:0.3:0.004 
F6 1:65.0 1:0.2:0.004 
F7 1:65.0 1:0.1:0.004 
F8 1:60.0 1:0.3:0.004 
F9 1:60.0 1:0.2:0.005 
F10 1:60.0 1:0.2:0.004 
F11 1:60.0 1:0.2:0.003 
F12 1:57.5 1:0.3:0.004 
F13 1:57.5 1:0.2:0.004 
F14 1:55.0 1:0.3:0.004 
F15 1:55.0 1:0.2:0.004 
 
Сyphetrylin inclusion in liposomes 
Cyphetrylin content in liposomes was performed using the working 
reference standard (RS) at 282±2 nm wavelength in Cary 100 
spectrophotometer (Agilent Technologies, Australia). As liposomes 
lipid components absorb in this spectrum, too, measurements were 
conducted in comparison with the “empty” liposomes solution. 
Cyphetrylin RS preparation: add about 15 ml 95% ethanol to 2.5 mg 
cyphetrylin. The resulting ethanol solution is transferred into a 25 
ml volumetric flask and diluted with ethanol. The solution to be used 
when fresh. 
Comparison solution preparation: 2 ml liposomal dispersion of 
“empty” liposomes is dissolved with ethanol in a 25 ml volumetric 
flask and diluted to the volume with ethanol. The solution is used 
when fresh. 
Test solution preparation: dissolve 2 ml cyphetrylin liposomal 
dispersion into a 25 ml volumetric flask. Add a small quantity of 
95% alcohol. Mix and dilute to the volume with alcohol.  
Measure the test solution's optical density in trays with 10 mm 
optical layer “thickness”, in maximum absorption compared with the 
comparison solution. Simultaneously, measure the optical density of 
the cyphetrylin RS solution vs that of the comparison solution. Using 
the formula (the dilution is identical), calculate the cyphetrylin 





А and А0–optical densities of the liposomal sample solutions and 
cyphetrylin RS, respectively; а0–weight of cyphetrylin RS, mg; 2–
volume of cyphetrylin liposomal sample, ml [16].  
Determination of cyphetrylin liposomal encapsulation 
efficiency 
As cyphetrylin is a hydrophobic substance and directly included in 
the lipid bilayer during liposome production, the encapsulation 
efficiency (EE) was determined as the ratio of API concentration in 
post-extrusion liposomal dispersion to cyphetrylin concentration in 
the dispersion after the lipid film hydration. The indicator expressed 





Сe–cyphetrylin concentration in dispersion after extrusion, mg/ml; 
Сh–cyphetrylin concentration in dispersion after hydration, mg/ml 
[16]. 
Determination of average diameter, polydispersity index (PDI) 
and the zeta potential for cyphetrylin liposomes 
The liposomal test by size and PDI was conducted using the 
correlation light scattering spectroscopy. Zeta potential of vesicles 
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was determined by measuring their electrophoretic mobility. All 
measurements used zeta sizer Nano-ZS 3600 (Malvern, U. K.). 100 μl 
test sample of freshly made liposomal dispersion was measured 
with an automatic pipette, poured into a 100 ml volumetric flask, 
and diluted in volume with water for injection. A 1 ml diluted sample 
was transferred to a polystyrene tray, placed into the zetasizer cell, 
and the above indicators were measured [17, 18].  
Determination for cyphetrylin liposomal dispersion viscosity 
Dynamic viscosity of cyphetrylin liposomal dispersion samples was 
determined using Vibro Viscometer SV-10 (AND Company Limited, 
Japan). All measurements were conducted at a temperature ranging 
from 21 °С to 25 °С. To this end, 10 ml of liposomal dispersion was 
poured onto the device's tray and measured [19]. 
RESULTS AND DISCUSSION 
In 2014−2017, the N. N. Blokhin National Medical Research Center of 
Oncology of the Ministry of Health of the Russian Federation 
researched on the development of a liposomal drug form of 
cyphetrylin. The components for cyphetrylin liposomal 
pharmaceutical dosage form were selected based on their functional 
purpose. Phosphatidylcholine of animal origin, derived from egg 
yolk (EPC), was used as the principal liposomal bilayer-forming 
excipient because of its properties. It has an acceptable phase-
transition temperature (+37 °С), good solubility in organic solvents, 
biocompatibility and natural origin. Natural phospholipids are 
preferred in pharmaceutical technology compared with their 
synthetic counterparts because they are available on a large scale, at 
a reproducible quality with low production costs, and manufactured 
with smaller quantities of chemical agents and solvents a higher 
yield of the finished product [20]. To enhance the bilayer rigidity 
and improve the phospholipid vesicle stability in the blood flow, 
cholesterol was added to liposomes. To protect the vesicles from 
being captured by reticuloendothelial cells after their 
introduction into the body and to slow down their clearance 
from the blood flow, we developed the stealth-liposomes with 
cyphetrylin. To this end; we injected the phospholipid “sewed” 
with PEG-DSPE into the bilipid layer of the pharmaceutical form, 
which increases osmotic pressure near the liposomes and 
prevents their discovery by macrophages. Using these 
components, we derived the model of the liposomal 
pharmaceutical dosage form with molar ratios of 
cyphetrylin/EPC at 1:70.0 and those of EPC/cholesterol/PEG-
DSPE at 1:0.2:0.003. The created cyphetrylin liposomal 
dispersion has 98% drug encapsulation rate and with 168±6 nm 
vesicle size [16]. 
To improve the injectable liposomal form of cyphetrylin, it was 
proposed to modify cyphetrylin liposomal composition by replacing 
EPC to SPC. Egg lecithin contains less unsaturated lipids than 
soybean lecithin (table 2) [19]. However, by forming different bonds 
with phospholipids, the hydrophobic active substance is 
encapsulated into the lipid bilayer. Based on this data, we suggested 
that the phosphatidylcholine (PC) origin may significantly impact 
the API encapsulation rate and that a large number of unsaturated 
bonds would lead to a lower lipid concentration in the drug and a 
higher API/PC ratio. 
 
Table 2: Egg and soybean lecithin lipid composition 
Chain composition Egg lecithin Soybean lecithin 
16:0 32 (33) 15 (14) 
16:1 5 (1) 4 
16:2 1 0 
18:0 14 (13) 1 (4) 
18:1 19 (32) 14 (11) 
18:2 13 (16) 59 (64) 
20:1 4 0 
20:2 6 0 
20:3 2 1 
20:4 2 (3) 4 
other 2 (5) 2 (3) 
saturated 46 16 
unsaturated 52 82 
 
The test was conducted by reducing SPC content in cyphetrylin/SPC 
from the initial 1:70.0 established for liposomes with EPC, as 
described above, and by varying the lipid composition ratio, with 
monitoring of such indicators as EE, average post-extrusion vesicle 
size and their fraction distribution index (PDI), zeta potential of 
liposomes and the resulting dispersion viscosity (table 3). 
 
Table 3: Characteristics of SPC-based investigatory compositions of cyphetrylin liposomal pharmaceutical form 
No EE, % Vesicle size, nm PDI Zeta potential, mV Viscosity, mPa·s 
F1 100.0±0.62 171±6.94 0.170±0.01 -13.2±0.75 9.8±1.19 
F2 100.0±1.51 167±6.05 0.282±0.01 -19.3±1.31 8.4±1.24 
F3 100.0±0.59 179±7.11 0.231±0.02 -16.4±1.10 5.6±0.33 
F4 99.0±0.82 173±7.01 0.177±0.01 -14.6±0.77 8.8±0.50 
F5 100.0±0.70 173±6.50 0.290±0.01 -18.1±0.95 10.8±0.62 
F6 100.0±0.33 174±5.91 0.195±0.01 -19.6±0.92 8.5±1.01 
F7 100.0±0.73 210±8.22 0.213±0.01 -19.3±1.02 6.3±0.74 
F8 100.0±0.97 174±7.15 0.230±0.01 -20.0±1.07 6.7±0.55 
F9 99.6±0.80 170±7.23 0.168±0.01 -19.2±0.72 10.7±0.43 
F10 100.0±0.54 176±6.02 0.212±0.01 -18.3±0.90 7.5±0.75 
F11 99.0±0.50 183±6.55 0.256±0.02 -18.0±1.25 6.5±0.67 
F12 95.6±0.88 185±7.30/11±0.02 0.195±0.01 -17.5±1.18 7.9±0.35 
F13 90.8±1.23 211±7.89 0.162±0.01 -17.3±1.30 6.2±0.49 
F14 93.1±1.04 152±6.70/11±0.10 0.099±0.01 -18.0±0.95 8.6±0.58 
F15 88.1±1.10 182±8.05 0.110±0.01 -19.7±0.85 6.6±0.71 
Note: Data given in mean±SD, n=3 
 
Dmitrieva et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 65-68 
68 
As a result, we established that the content of all lipid components 
influenced cyphetrylin liposomal EE. When the overall lipid 
concentration decreased, the 100% maximum encapsulation was 
achieved in a liposomal composition No. 10 with the molar ratio of 
cyphetrylin/SPC at 1:60.0 and those of SPC/cholesterol/PEG-DSPE 
at 1:0.2:0.004. Further increase in cyphetrylin/SPC ratio resulted in 
a significant reduction of the encapsulation rate to ~91%, which 
may have increased to 95.6% at a higher cholesterol content (F12). 
A more significant increase in its concentration is not appropriate 
due to the deterioration of the dispersion technological properties 
resulting from the rigid liposomal structure. We also noted that both 
the decrease and the increase in pegylated phospholipid content 
contribute to a slight reduction in cyphetrylin vesicular EE. 
When reviewing other quality parameters, we did not establish any 
correlation between their values and the liposomal lipid 
composition. The size distribution curves review suggested that 
virtually all model liposomes' diameter did not exceed the 
preferable one for therapeutic use, 220 nm, and PDI are below 0.3, 
which testifies to the narrow size distribution of the particles [21]. 
The only exception is being F8: the vesicle diameter amounted to 
243 nm. F12 and F14 displayed the bimodal size distribution, which 
points to two vesicle fractions with different sizes. Vesicle size 
reduction as the cholesterol level increases may be accounted for by 
a higher packing density. The electrophoretic mobility measurement 
analysis showed that cyphetrylin liposomes charge of the prepared 
compositions ranges from-13.2 mV to-20.0 mV, and dispersion 
dynamic viscosity range from 5.6−10.8 mPa·s. 
The comparative data analysis by quality attributes of the 
investigated compositions allowed to select the preferable model for 
the production of cyphetrylin liposomal pharmaceutical dosage form 
based on soybean lecithin with the following molar ratios of 
components: cyphetrylin/SPC at 1:60.0 and SPC/cholesterol/PEG-
DSPE at 1:0.2:0.004. 
The conducted study suggests that phospholipids derived from 
different sources may influence active hydrophobic substance 
loading into a liposomal membrane. If cyphetrylin was included, the 
SPC selected as the primary, bilayer-forming component in 
liposomal pharmaceutical dosage form for further research had the 
advantage. 
CONCLUSION 
Cyphetrylin, the hypothalamic hormone somatostatin analogue with 
antitumor activity, is a promising drug to treat many cancers, 
including neuroendocrine tumors. Cyphetrylin liposomal 
encapsulation was proposed for the injectable pharmaceutical 
dosage form creation to overcome the active substance's low water 
solubility. The conducted research helped select the desirable model 
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